[go: up one dir, main page]

MX2010010265A - Methods for treating psoriasis. - Google Patents

Methods for treating psoriasis.

Info

Publication number
MX2010010265A
MX2010010265A MX2010010265A MX2010010265A MX2010010265A MX 2010010265 A MX2010010265 A MX 2010010265A MX 2010010265 A MX2010010265 A MX 2010010265A MX 2010010265 A MX2010010265 A MX 2010010265A MX 2010010265 A MX2010010265 A MX 2010010265A
Authority
MX
Mexico
Prior art keywords
methods
treating psoriasis
subject
psoriasis
treating
Prior art date
Application number
MX2010010265A
Other languages
Spanish (es)
Inventor
Joaquin Mario Valdes
Susan K Paulson
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2010010265A publication Critical patent/MX2010010265A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
MX2010010265A 2008-03-18 2009-03-11 Methods for treating psoriasis. MX2010010265A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6984008P 2008-03-18 2008-03-18
US9527508P 2008-09-08 2008-09-08
US20790409P 2009-02-18 2009-02-18
PCT/US2009/036765 WO2009117289A2 (en) 2008-03-18 2009-03-11 Methods for treating psoriasis

Publications (1)

Publication Number Publication Date
MX2010010265A true MX2010010265A (en) 2010-09-30

Family

ID=41091468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010265A MX2010010265A (en) 2008-03-18 2009-03-11 Methods for treating psoriasis.

Country Status (16)

Country Link
US (2) US8178092B2 (en)
EP (2) EP2810954A3 (en)
JP (1) JP2011515404A (en)
KR (1) KR20100126515A (en)
CN (1) CN102037011A (en)
AU (1) AU2009225797A1 (en)
BR (1) BRPI0908715A2 (en)
CA (1) CA2717569A1 (en)
HK (1) HK1203516A1 (en)
IL (1) IL208069A0 (en)
MX (1) MX2010010265A (en)
NZ (2) NZ602511A (en)
RU (2) RU2497545C2 (en)
SG (1) SG188909A1 (en)
TW (2) TWI461210B (en)
WO (1) WO2009117289A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
KR20150038227A (en) * 2007-01-16 2015-04-08 애브비 인코포레이티드 Methods for treating psoriasis
RU2476442C2 (en) 2007-03-29 2013-02-27 Эббот Лэборетриз Crystalline human il-12 antibodies
KR20100126515A (en) * 2008-03-18 2010-12-01 아보트 러보러터리즈 How to treat psoriasis
US20090269398A1 (en) * 2008-04-26 2009-10-29 Vilambi Nrk Reddy Compositions for the encapsulation of natural product extracts in oil medium in hard gelatin capsules and a method of encapsulation
CN104398471A (en) * 2008-11-28 2015-03-11 Abbvie公司 Stable antibody compositions and methods for stabilizing same
AU2010291927A1 (en) * 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
JO3244B1 (en) 2009-10-26 2018-03-08 Amgen Inc Proteins bind to human IL-23 antigens
WO2011146727A1 (en) * 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
MX2013003920A (en) * 2010-10-06 2013-06-03 Abbvie Inc Methods for treating psoriasis.
EP3869201A1 (en) * 2013-03-12 2021-08-25 Abbott Laboratories Reagents, systems and methods for analyzing white blood cells
CN105209064A (en) * 2013-03-15 2015-12-30 美国安进公司 Methods of treating psoriasis using anti-IL-23 antibodies
AP2015008801A0 (en) * 2013-03-15 2015-10-31 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN112689512B (en) * 2018-05-29 2025-09-05 艾比中心有限责任公司 Compositions and methods for treating psoriasis
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914A (en) 1849-11-27 Propeller
US128A (en) 1837-02-16 Holdback for sleds
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991005058A1 (en) 1989-10-05 1991-04-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
ES2341666T3 (en) 1991-12-02 2010-06-24 Medimmune Limited PRODUCTION OF AUTHORTIC BODIES OF REPERTORIES OF ANTIQUE RPOS SEGMENTS EXPRESSED ON THE FAGOS SURFACE.
JPH07509137A (en) 1992-07-24 1995-10-12 セル　ジェネシス，インク． Production of xenoantibodies
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
PT614984E (en) 1993-03-05 2001-12-28 Bayer Ag ANTI-TNF HUMAN ANTIBODIES
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5562138A (en) * 1994-10-13 1996-10-08 The Longaberger Company Bowing press
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CN1300173C (en) 1996-02-09 2007-02-14 艾博特生物技术有限公司 Human antibodies that bind human TNFα
AU7257696A (en) 1996-10-11 1998-05-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
PT936923E (en) 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology BLENDING OF TNFALFA AND IL-12 IN THERAPY
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
HUP0104439A3 (en) 1997-03-18 2002-08-28 Basf Ag Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2297692A1 (en) 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
EP0969867B1 (en) 1997-10-31 2004-09-01 Wyeth Use of anti-il-12 antibodies in transplantation rejection
KR100764256B1 (en) 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 Antibodies Against Human Interleukin-12
US20020161199A1 (en) 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
EP1137766B1 (en) 1998-12-09 2005-09-28 Protein Design Labs, Inc. Use of il-12 antibodies to treat psoriasis
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DK2168984T3 (en) 1999-03-25 2012-12-10 Abbott Gmbh & Co Kg Human antibodies that bind human IL-12 and methods for its production
PL202058B1 (en) * 1999-08-09 2009-05-29 Merck Patent Gmbh Multiple cytokine−antibody complexes
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
KR20030074693A (en) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2002098445A1 (en) 2001-05-30 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Protein preparation
WO2002097048A2 (en) 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2003097082A2 (en) * 2002-05-17 2003-11-27 Protein Design Labs Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
AU2003251906B2 (en) 2002-07-12 2008-12-04 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US7608260B2 (en) 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
KR101224235B1 (en) 2003-04-11 2013-01-25 메디뮨 엘엘씨 Recombinant IL-9 Antibodies and Uses Thereof
EP1623011B1 (en) 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
JP2007503839A (en) * 2003-09-04 2007-03-01 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Novel UBP8rp polypeptide and its use in the treatment of psoriasis
JP4219932B2 (en) 2003-10-01 2009-02-04 協和発酵キリン株式会社 Antibody stabilization method and stabilized solution antibody preparation
CA2550505A1 (en) 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
SG10201900535UA (en) 2003-12-23 2019-02-27 Genentech Inc Novel anti-il 13 antibodies and uses thereof
JP2007522157A (en) 2004-02-12 2007-08-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Highly concentrated liquid formulation of anti-EGFR antibody
RU2292215C2 (en) * 2004-05-21 2007-01-27 Дмитрий Васильевич Николенко Method and complex for psoriasis production
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
ZA200700947B (en) 2004-07-23 2008-06-25 Genentech Inc Crystallization of antibodies or fragments thereof
SG158150A1 (en) 2004-12-21 2010-01-29 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses
CA2898009C (en) * 2005-05-16 2018-03-27 Rebecca S. Hoffman Use of tnfa inhibitor for treatment of erosive polyarthritis
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
KR20080098504A (en) 2006-02-03 2008-11-10 메디뮨 엘엘씨 Protein formulations
EP2636754B1 (en) 2006-09-11 2015-03-04 Celera Corporation Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
SG175622A1 (en) 2006-10-13 2011-11-28 Centocor Ortho Biotech Inc Enhancement of hybridoma fusion efficiencies through cell synchronization
KR20150038227A (en) 2007-01-16 2015-04-08 애브비 인코포레이티드 Methods for treating psoriasis
RU2476442C2 (en) 2007-03-29 2013-02-27 Эббот Лэборетриз Crystalline human il-12 antibodies
KR20100126515A (en) 2008-03-18 2010-12-01 아보트 러보러터리즈 How to treat psoriasis
CN104398471A (en) 2008-11-28 2015-03-11 Abbvie公司 Stable antibody compositions and methods for stabilizing same
AU2010291927A1 (en) 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
MX2013003920A (en) 2010-10-06 2013-06-03 Abbvie Inc Methods for treating psoriasis.
WO2012094623A2 (en) 2011-01-07 2012-07-12 Abbott Laboratories Anti-il-12/il-23 antibodies and uses thereof
WO2012097288A1 (en) 2011-01-14 2012-07-19 Abbott Laboratories Human antibodies that bind the p40 subunit of human il-12/il-23 and uses therefor

Also Published As

Publication number Publication date
SG188909A1 (en) 2013-04-30
TW201513883A (en) 2015-04-16
WO2009117289A3 (en) 2010-04-22
HK1203516A1 (en) 2015-10-30
US8178092B2 (en) 2012-05-15
TWI461210B (en) 2014-11-21
WO2009117289A2 (en) 2009-09-24
CA2717569A1 (en) 2009-09-24
IL208069A0 (en) 2010-12-30
BRPI0908715A2 (en) 2016-05-03
TW200948379A (en) 2009-12-01
EP2274333A4 (en) 2011-06-15
RU2013132928A (en) 2015-01-27
RU2497545C2 (en) 2013-11-10
KR20100126515A (en) 2010-12-01
EP2274333A2 (en) 2011-01-19
US20120219562A1 (en) 2012-08-30
AU2009225797A1 (en) 2009-09-24
CN102037011A (en) 2011-04-27
EP2810954A3 (en) 2015-03-18
US20100028363A1 (en) 2010-02-04
JP2011515404A (en) 2011-05-19
EP2810954A2 (en) 2014-12-10
RU2010142309A (en) 2012-04-27
US8945545B2 (en) 2015-02-03
NZ587765A (en) 2013-02-22
NZ602511A (en) 2014-03-28

Similar Documents

Publication Publication Date Title
MX2010010265A (en) Methods for treating psoriasis.
MX2009007570A (en) Methods for treating psoriasis.
SG179135A1 (en) Methods for treating psoriasis
WO2012048134A3 (en) Methods for treating psoriasis
MX2010009724A (en) Methods of treating inflammatory pain.
MX2009009079A (en) Engineered anti-il-23p19 antibodies.
MX2009009080A (en) Engineered anti-il-23p19 antibodies.
SG165322A1 (en) Engineered anti-il-23 antibodies
MX2009009283A (en) Engineered anti-il-23r antibodies.
PH12013500355A1 (en) Engineered anti-tslp antibody
MX341578B (en) Treatment of osteoarthritis and pain.
HK1203519A1 (en) Methods of treatment using an antibody against interferon gamma
PH12013500810B1 (en) Anti-il-23 antibodies
PH12013502230A1 (en) Multispecific antibodies
MX2012014080A (en) Uses and compositions for treatment of hidradenitis suppurativa (hs).
TN2015000050A1 (en) Methods of treating a tauopathy
MX2011010955A (en) Adjuvant cancer therapy.
MX2014011134A (en) Carbamate compounds and of making and using same.
MX349886B (en) Anti-pseudomonas psl binding molecules and uses thereof.
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
MX2014000531A (en) Methods and compositions for treating asthma using anti-il-13 antibodies.
MX2011006725A (en) Combination of aurora kinase inhibitors and anti-cd20 antibodies.
UA102097C2 (en) Method for the treatment of an inflammatory disease using a compound neutralizing gm-csf and a compound neutralizing il-17
WO2011135544A3 (en) Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy
WO2011083483A3 (en) Method for treatment of inflammatory disease and disorder

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration